Skandinaviska Enskilda Banken AB publ Acquires 50,302 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 56.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 139,849 shares of the company’s stock after acquiring an additional 50,302 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.45% of Medpace worth $57,611,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the company. Signaturefd LLC raised its stake in shares of Medpace by 4.9% during the second quarter. Signaturefd LLC now owns 559 shares of the company’s stock worth $230,000 after buying an additional 26 shares during the last quarter. Wealth Alliance boosted its holdings in Medpace by 2.9% during the second quarter. Wealth Alliance now owns 970 shares of the company’s stock worth $399,000 after purchasing an additional 27 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in Medpace by 0.7% during the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock worth $1,787,000 after purchasing an additional 32 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Medpace by 5.3% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock valued at $316,000 after acquiring an additional 39 shares during the last quarter. Finally, Journey Advisory Group LLC lifted its stake in Medpace by 1.9% in the second quarter. Journey Advisory Group LLC now owns 2,390 shares of the company’s stock valued at $984,000 after acquiring an additional 44 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Trading Up 2.2 %

Medpace stock opened at $369.18 on Friday. The stock has a fifty day simple moving average of $379.70 and a two-hundred day simple moving average of $392.28. The firm has a market cap of $11.44 billion, a price-to-earnings ratio of 37.63, a PEG ratio of 1.74 and a beta of 1.36. Medpace Holdings, Inc. has a 12 month low of $227.21 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 22nd. The company reported $2.75 EPS for the quarter, topping the consensus estimate of $2.54 by $0.21. The firm had revenue of $528.10 million during the quarter, compared to analyst estimates of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. Medpace’s revenue was up 14.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.93 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Analysts Set New Price Targets

MEDP has been the subject of a number of research reports. William Blair restated an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. Robert W. Baird decreased their target price on shares of Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a report on Wednesday, July 24th. Mizuho assumed coverage on shares of Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price target on the stock. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Guggenheim dropped their price target on shares of Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research report on Wednesday, July 24th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Medpace presently has a consensus rating of “Moderate Buy” and an average price target of $423.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.